Travere Therapeutics, Inc. — Cyborg Score 8/10

Strategic Profile

FILSPARI (sparsentan) is a once-daily oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy, and the company also markets Thiola and Thiola EC for cystinuria treatment. The company is pursuing FDA approval for FILSPARI in FSGS with a PDUFA target action date of January 13, 2026.

Cyborg Score Rationale

The company achieved $410.5 million in total 2025 product sales with FILSPARI showing 144% YoY growth. Travere ended 2025 with $323 million in cash and equivalents, providing strong financial positioning for pipeline advancement and commercial execution in the competitive rare disease space.

Top Insights

• U.S. FILSPARI reached 908 new prescriber starts and $103 million in net product sales in Q4 2025
• Company expanded field team to over 100 personnel targeting high prescriber overlap between IgAN and FSGS
• Phase 3 HARMONY study of pegtibatinase for classical HCU restarting in Q1 2026
• Partner Chugai Pharmaceutical expected to submit NDA for sparsentan in Japan in 2026

Named Competitors

• FSGS and IgAN treatments — Developing therapies for kidney disease
• Cystinuria treatment — Rare disease biopharmaceutical
• Rare kidney disease focus — Lupus nephritis and other kidney disorders

Recent Developments

• (January 2026) 2025 U.S. net product sales reached $410 million
• (January 2026) FILSPARI FSGS approval decision expected January 13, 2026
• (November 2025) Phase 3 DUPLEX study data presented showing FILSPARI FSGS efficacy
• (December 2025) Strategic inducement equity grants to expand leadership team

Open the full interactive Travere Therapeutics, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.